

**IN THE CLAIMS:**

Please cancel the previous versions of claims 9 and 11 and insert the amended versions of claims 9 and 11 as follows:

9. (Once Amended) An assay for determining the concentration of soluble epidermal growth factor receptor and full-length epidermal growth factor receptor in a biological sample from a human patient, the assay comprising:

- a) obtaining a biological sample from the patient;
- b) contacting an amount of a first purified antibody that specifically reacts with a first epitope of the extracellular ligand binding domain of sErbB1 with the patient biological sample to be tested, wherein the first purified antibody is modified with a first labeling moiety;
- c) contacting the sample with an amount of a second purified antibody that specifically reacts with a second epitope of the extracellular ligand binding domain of sErbB1, wherein the second purified antibody is modified with a second labeling moiety, and wherein the second purified antibody does not competitively inhibit the binding of the first purified antibody; and
- d) detecting the co-presence of the first and second labels to determine the concentration of the soluble epidermal growth factor receptor complexed with the antibodies; wherein one of the antibodies is chosen from the group consisting of: Mab R.1 and antibodies which competitively inhibit the binding of Mab R.1 to ErbB1; and wherein the other antibody is chosen from the group consisting of Mab 528 and antibodies which

264

competitively inhibit the binding of Mab 528 to ErbB1.

---

11. (Once Amended) The assay of Claim 9 wherein the patient biological sample is  
p65 chosen from the group consisting of blood, serum and plasma.

---